Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors

Authors


  • *A preliminary report of these findings was presented at the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Sydney, Australia, 19–21 July 2007.

Dr Kevin E. Yarasheski, PhD, Washington University School of Medicine, 4940 Parkview Place, Metabolism Division, BOX 8127, St. Louis, MO 63110, USA. Tel: +1 314 362 8173; fax: +1 314 362 7641; e-mail: key@wustl.edu

Abstract

Objective

People living with HIV infection are at increased risk for developing cardiovascular disease (CVD). Safe and effective interventions for lowering CVD risk in HIV infection are high priorities. We conducted a prospective, randomized, controlled study to evaluate whether a yoga lifestyle intervention improves CVD risk factors, virological or immunological status, or quality of life (QOL) in HIV-infected adults relative to standard of care treatment in a matched control group.

Methods

Sixty HIV-infected adults with mild–moderate CVD risk were assigned to 20 weeks of supervised yoga practice or standard of care treatment. Baseline and week 20 measures were: 2-h oral glucose tolerance test with insulin monitoring, body composition, fasting serum lipid/lipoprotein profile, resting blood pressures, CD4 T-cell count and plasma HIV RNA, and the Medical Outcomes Study Short Form (SF)-36 health-related QOL inventory.

Results

Resting systolic and diastolic blood pressures improved more (P=0.04) in the yoga group (−5 ± 2 and −3 ± 1 mmHg, respectively) than in the standard of care group (+1 ± 2 and+2 ± 2 mmHg, respectively). However, there was no greater reduction in body weight, fat mass or proatherogenic lipids, or improvements in glucose tolerance or overall QOL after yoga. Immune and virological status was not adversely affected.

Conclusion

Among traditional lifestyle modifications, yoga is a low-cost, simple to administer, nonpharmacological, popular behavioural intervention that can lower blood pressure in pre-hypertensive HIV-infected adults with mild–moderate CVD risk factors.

Ancillary